EUCAST Subcommittee for Detection of Resistance Mechanisms (ESDReM)

Christian G. Giske, MD/PhD
Chairman of ESDReM
Karolinska University Hospital and EUCAST
ECCMID, 27 April 2013
The background

• Guidance on methods of detection and characterization of resistance mechanisms are required to tie in with
  – The EUCAST MIC breakpoints
  – The EUCAST disk diffusion method
  – EUCAST Expert Rules
  – The ECDC requirements for update of the EARS-Net manual
The remit

• To develop practical guidelines for detection of specific antimicrobial resistance mechanisms of clinical and/or epidemiological importance.
• The guidance will include:
  – Definition of the mechanisms.
  – Explanation of the clinical and/or public health need for detection of the mechanisms.
  – An outline description of recommended methods of detection.
  – References to detailed descriptions of the methods.
• Draft guidelines that have been subject to wide consultation via established EUCAST procedures and ECDC focal points
Mechanisms and bacteria

- Methicillin-resistant *S. aureus*
- Vancomycin low-level resistance in *S. aureus* (VISA/heteroVISA)
- Vancomycin-resistant enterococci
- Penicillin non-susceptible *S. pneumoniae*
- Extended-spectrum β-lactamase producing Enterobacteriaceae
- Acquired AmpC-producing Enterobacteriaceae
- Acquired carbapenemases in Enterobacteriaceae
Timeline

- February 2012: recruiting of members
- April 2012 (at ECCMID): first (and only) meeting, sharing the work between members
- December 2012: open consultation (one month)
- January 2013: consultation closes
- February-April 2013: revision of the document
- May 2013: final consultation
- June 2013: revision
- July 2013: approval by the steering committee
Members of the SC

- Christian G. Giske (Chair; Sweden, EUCAST and EARS-Net)
- Luis Martinez-Martinez (Spain)
- Rafael Canton (Spain and EUCAST)
- Stefania Stefani (Italy)
- Robert Skov (Denmark)
- Youri Glupczynski (Belgium)
- Patrice Nordmann (France)
- Mandy Wootton (UK)
- Vivi Miriagou (Greece)
- Gunnar Skov Simonsen (Norway and EARS-Net)
- Helena Zemlickova (Czech republic and EARS-Net)
- James Cohen-Stuart (Netherlands)
- Marek Gniadkowski (Poland)
The guidelines

EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance

Version 1.0
EUCAST, April 2013

Christian G. Giske (Sweden, EUCAST Steering Committee and EARS-Net Coordination Group, chairman), Luis Martinez-Martinez (Spain and EUCAST Steering Committee), Rafael Cantón (Spain and chairman of EUCAST), Stefania Stefani (Italy), Robert Skov (Denmark and EUCAST Steering Committee), Yvonne Gliczinski (Belgium), Patrice Nordmann (France), Mandy Wootton (UK), Vivi Miragou (Greece), Gunnar Skov Simonson (Norway and EARS-Net Coordination Group), Helena Zemičlova (Czech Republic and EARS-Net Coordination Group), James Cohen-Stuart (The Netherlands) and Marek Gniadkowski (Poland).
2. CARBAPENEMASES IN ENTEROBACTERIACEAE

<table>
<thead>
<tr>
<th>Importance of detection of resistance mechanism</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Required for antimicrobial susceptibility categorisation</td>
<td>No</td>
</tr>
<tr>
<td>Infection control</td>
<td>Yes</td>
</tr>
<tr>
<td>Public health</td>
<td>Yes</td>
</tr>
</tbody>
</table>

2.1 Definition
Carbapenemases are β-lactamases hydrolyzing penicillins, in most cases cephalosporins, and to varying degrees carbapenems and monobactams (the latter are not hydrolyzed by metallo-β-lactamases).
Q1 and Q2
When should screening be carried out?

<table>
<thead>
<tr>
<th>Carbapenem</th>
<th>MIC (mg/L)</th>
<th>Disk diffusion zone diameter (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S/I-Breakpoint</td>
<td>Screening cut-off</td>
</tr>
<tr>
<td>Meropenem¹</td>
<td>≤2</td>
<td>&lt;0.125</td>
</tr>
<tr>
<td>Imipenem</td>
<td>≤2</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Ertapenem³</td>
<td>≤0.5</td>
<td>&gt;0.125</td>
</tr>
</tbody>
</table>

¹Meropenem offers the best balance between sensitivity and specificity in the detection of putative carbapenemase-producers.

²In rare cases OXA-48-producing Enterobacteriaceae have presented with zone diameters of 24-26 mm, for which reason 27 mm may be considered as a screening cut-off during outbreaks. It should be noted that this cut-off will bisect the wild-type.

³Ertapenem has high sensitivity, but low specificity for prediction of carbapenemase-producing Enterobacteriaceae, and is for this reason not recommended.
Phenotypic confirmation methods

Meropenem <25 mm with disk-diffusion or MIC >0.12 mg/L in all Enterobacteriaceae

Synergy with APBA/PBA only
- KPC (or other class A carbapenemase)

Synergy with APBA/PBA AND cloxacillin
- AmpC (chromosomal and plasmid-acquired)
- AmpC plus porin loss

Synergy with DPA only
- Metallo-beta-lactamase (MBL)

No synergy¹
- ESBL plus porin loss AND OXA-48²

¹ Combination of KPC and MBL can also produce no synergy. Normally these isolates will have very high resistance levels to carbapenems. They are easiest to detect with molecular methods.
² High-grade temocillin resistance (>32 mg/L, temocillin (30 µg) zone diameter ≤11 mm) is a phenotypic indicator of OXA-48.
3. EXTENDED-SPECTRUM β-LACTAMASES (ESBLs) IN ENTEROBACTERIACEAE

<table>
<thead>
<tr>
<th>Importance of detection of resistance mechanism</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Required for antimicrobial susceptibility categorisation</td>
<td>No</td>
</tr>
<tr>
<td>Infection control</td>
<td>Yes</td>
</tr>
<tr>
<td>Public health</td>
<td>Yes</td>
</tr>
</tbody>
</table>

3.1 Definition

ESBLs are β-lactamases conferring resistance against oxyimino-β-lactam compounds (cefuroxime, third- and fourth-generation cephalosporins and aztreonam) and are resistant to most penicillins, cephalosporins (except for cephemycins) and monobactams. Most of ESBLs belong to the Ambler class A of β-lactamases and are inhibited by β-lactam inhibitors (clavulanate, sulbactam and tazobactam).
When should ESBL-testing be done?

<table>
<thead>
<tr>
<th>Method</th>
<th>Antibiotic</th>
<th>Conduct ESBL-testing if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broth or agar dilution</td>
<td>Cefotaxime</td>
<td>MIC &gt; 1 mg/L</td>
</tr>
<tr>
<td></td>
<td>Ceftazidime</td>
<td>MIC &gt; 1 mg/L</td>
</tr>
<tr>
<td></td>
<td>Cefpodoxime</td>
<td>MIC &gt; 1 mg/L</td>
</tr>
<tr>
<td>Disk diffusion</td>
<td>Cefotaxime</td>
<td>Inhibition zone &lt; 21 mm</td>
</tr>
<tr>
<td></td>
<td>(5 μg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceftazidime</td>
<td>Inhibition zone &lt; 22 mm</td>
</tr>
<tr>
<td></td>
<td>(10 μg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cefpodoxime</td>
<td>Inhibition zone &lt; 21 mm</td>
</tr>
<tr>
<td>Automated systems</td>
<td>Cefotaxime</td>
<td>MIC &gt; 1 mg/L</td>
</tr>
<tr>
<td></td>
<td>Ceftazidime</td>
<td>MIC &gt; 1 mg/L</td>
</tr>
</tbody>
</table>
ESBL SCREENING:
cefotaxime I/R and/or ceftazidime I/R using EUCAST breakpoints

No ESBL

Yes

species dependent ESBL confirmation

Group 1:
E.coli, Klebsiella spp., P. mirabilis, Salmonella spp.,
Shigella spp., Raoullella spp.

ESBL CONFIRMATION
with ceftazidime and cefotaxime +/- clavulanic acid

Negative: No ESBL
Off range
Positive: ESBL

Group 2:
Enterobacteriaceae with inducible chromosomal AmpC:
Enterobacter spp., Citrobacter freundii, Morganella morganii,
Providencia spp, Serratia spp., Hafnia alvei.

ESBL CONFIRMATION
with cefepime +/- clavulanic acid

Negative: no ESBL
Off range
Positive: ESBL

1: If cefoxitin MIC > 8 mg/L, perform cefepime +/- clavulanic acid confirmation test
2: Genotypic or phenotypic confirmation of acquired AmpC is recommended in group 1 Enterobacteriaceae isolates with negative ESBL confirmation test.
<table>
<thead>
<tr>
<th>Method</th>
<th>Antibiotic</th>
<th>Disk/tablet load</th>
<th>Confirmation is positive if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etest ESBL</td>
<td>Cefotaxime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio $^1$ $\geq$ 8 or deformation ellipse / phantom zone present</td>
</tr>
<tr>
<td></td>
<td>Ceftazidime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio $^1$ $\geq$ 8 or deformation ellipse / phantom zone present</td>
</tr>
<tr>
<td>Combination disk diffusion test (CDT)</td>
<td>Cefotaxime +/- clavulanic acid</td>
<td>Cefotaxime 30 ug +/- clavulanic acid 10 ug</td>
<td>$\geq$ 5 mm increase in inhibition zone $^2$</td>
</tr>
<tr>
<td></td>
<td>Ceftazidime +/- clavulanic acid</td>
<td>Ceftazidime 30 ug +/- clavulanic acid 10 ug</td>
<td>$\geq$ 5 mm increase in inhibition zone $^2$</td>
</tr>
<tr>
<td>Broth microdilution</td>
<td>Cefotaxime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio $^1$ $\geq$ 8</td>
</tr>
<tr>
<td></td>
<td>Ceftazidime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio $^1$ $\geq$ 8</td>
</tr>
<tr>
<td>Double disk synergy test (DDST)</td>
<td>Cefepime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio $^1$ $\geq$ 8</td>
</tr>
<tr>
<td></td>
<td>Cefotaxime, ceftazidime and cefepime</td>
<td>-</td>
<td>Expansion of indicator cephalosporin inhibition zone towards amoxicillin-clavulanic acid disc</td>
</tr>
</tbody>
</table>
Q4
5. DETECTION OF METHICillin RESISTANCE IN STAPHYLOCOCCUS AUREUS (MRSA)

<table>
<thead>
<tr>
<th>Importance of detection of resistance</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Required for antimicrobial susceptibility categorisation</td>
<td>Yes</td>
</tr>
<tr>
<td>Infection control</td>
<td>Yes</td>
</tr>
<tr>
<td>Public health</td>
<td>Yes</td>
</tr>
</tbody>
</table>

5.1 Definition

*S. aureus* isolates with an auxiliary penicillin binding protein 2 (PBP2a or the recently discovered PBP2c) to which β-lactam agents, except for the novel class of cephalosporins having anti-MRSA activity, have little or no affinity.
6. NON-SUSCEPTIBILITY TO GLYCOPEPTIDES IN STAPHYLOCOCCUS AUREUS

<table>
<thead>
<tr>
<th>Importance of detection of resistance</th>
<th>Required for antimicrobial susceptibility categorisation</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection control</td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>Public health</td>
<td></td>
<td>Yes</td>
</tr>
</tbody>
</table>

6.1 Definition

GRSA: Glycopeptide resistant S. aureus
S. aureus isolates with high-level resistance to vancomycin (MIC > 8 mg/L).

GISA: glycopeptide intermediate S. aureus
S. aureus isolates with low-level resistance to vancomycin (MIC 4 - 8 mg/L).

hGISA: Heterogeneous glycopeptide intermediate S. aureus
S. aureus isolates with incomplete low-level resistance to vancomycin (MICs ≤ 2mg/L) but with minority populations (1 in 10^6 cells) with vancomycin MIC > 2 mg/L by population analysis.
6.4 Recommended methods for detection

Disk diffusion can **NOT** be used to test for either hGISA or GISA.

6.4.1 MIC determination

BMD using EUCAST methodology is the gold standard (ISO 20776-1), but MICs may also be determined by gradient strips, agar dilution or automated systems. It should be noted that the results using gradient strips are 0.5 - 1 dilution steps higher than the results obtained by BMD (7). The EUCAST breakpoint for resistance to vancomycin in *S. aureus* is MIC > 2 mg/L.

6.4.2 Specific tests for hGISA

GISA is detected by measuring the MIC, but this is not the case for hGISA. Detection of hGISA has proven difficult. Detection is therefore divided into screening and confirmation. For screening a number of specialised methods have been designed.
7. DETECTION OF VANCOMYCIN RESISTANCE IN ENTEROCOCCUS FAECALIS AND ENTEROCOCCUS FAECIUM

<table>
<thead>
<tr>
<th>Importance of detection of resistance</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Required for antimicrobial susceptibility categorisation</td>
<td>Yes</td>
</tr>
<tr>
<td>Infection control/public health</td>
<td>Yes</td>
</tr>
<tr>
<td>Public health</td>
<td>Yes</td>
</tr>
</tbody>
</table>

7.1 Definition

*Enterococcus faecalis* or *Enterococcus faecium* with resistance to vancomycin (VRE) (vancomycin MIC > 4 mg/L).

7.2 Mechanism of resistance

Clinically relevant resistance is most often mediated by plasmid-encoded VanA and VanB ligases that confer replacement of D-Ala in the peptidoglycan with D-Lac.
7.4 Recommended methods for detection

Vancomycin resistance can be detected by MIC-determination, disk diffusion and the breakpoint agar method. For all three methods it is essential that plates are incubated for a full 24hrs in order to capture inducible resistance.

All three methods readily detect vanA-mediated resistance. Detection of vanB-mediated resistance is more challenging. MIC determination using agar or broth dilution works with high accuracy but is seldom used in routine laboratories. Reports show that detection of vanB-mediated resistance is problematic for automated methods (Swenson, Endtz, Klare). Disk diffusion using a 5μg vancomycin disk performs well provided the guidelines for reading as specified by EUCAST are followed meticulously (data from EUCAST Reference Laboratory, Växjö, Sweden).
8. DETECTION OF PENICILLIN NON-SUSCEPTIBILITY IN STREPTOCOCCUS PNEUMONIAE

### Importance of detection of resistance

<table>
<thead>
<tr>
<th>Importance</th>
<th>Required for antimicrobial susceptibility categorisation</th>
<th>Infection control</th>
<th>Public health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Required for antimicrobial susceptibility categorisation</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Infection control</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public health</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 8.1 Definition

*S. pneumoniae* isolates with reduced susceptibility (non-wild-type MICs) to penicillin due to the presence of modified penicillin binding proteins (PBP) with lower affinity to β-lactams.
Conclusions

- Pan-European guidelines are soon to be available
- Scrutiny and constructive feedback from national methodology committees is pivotal to ensure that the guidelines are improved over time
- My prediction: there will be a need for this work also beyond July 2013
- European standardization may be helpful for EARS-Net, but hopefully even more so for laboratories, patients and infection control